The manufacturer of testosterone replacement therapy Testogel says it will work with health professionals to fill the void left by the withdrawal of competitor product, Axiron
Eli Lilly has this month written to doctors to advise that it no longer holds the rights to distribute Axiron (2% w/v transdermal testosterone solution).
These now revert to the original manufacturer, Acrux, and according to the doctors letter, it has “no immediate plans to commercialise Axiron in Australia…”
The Lilly licensing agreement finishes on 4 December, and its letter said “pharmacies may still have residual stock after this date but will not be able to order further stock.”
The letter advises that a number of testosterone therapeutic alternatives are available and registered with the ARTG.
Now, Besins Healthcare, manufacturer of Testogel (1% transdermal testosterone gel) says it is also writing to doctors to provide prescribing information that may support the transition of men treated with Axiron to Testogel sachets or metered dose pump packs.
“Today’s news that Eli Lilly is discontinuing supply of Axiron in Australia is significant for doctors and the 2,500 men estimated to be using this therapy,” said Geoff Blundell, managing director Australia and New Zealand for Besins Healthcare.
“Men who are receiving Axiron need to visit their doctors and seek an alternative prescription if they wish to continue testosterone replacement therapy,” he said.
However, he warns that the unexpected deletion of Axiron is likely to place pressure on Testogel stock levels.
“We are working to upscale production, but may face short-term supply issues for Testogel sachets,” he said. “We do however have ample supply of the metered dose pump pack”.
Eli Lilly says health professionals or patients wanting more information on the withdrawal of Axiron should contact their medical information line on (02) 9325 4622.